Two doses of Covaxin, also known as BBV152 are only 50% effective against symptomatic coronavirus disease, the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal showed. For the study, a total of 2,714 symptomatic hospital workers at the All India Institute of Medical Sciences (AIIMS) here, who were primarily offered Covaxin were assessed, from April 15 May 15.
Two doses of Covaxin, also known as BBV152 are only 50% effective against symptomatic coronavirus disease, the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal showed. For the study, a total of 2,714 symptomatic hospital workers at the All India Institute of Medical Sciences (AIIMS) here, who were primarily offered Covaxin were assessed, from April 15 May 15.
139.jpeg)
260.jpeg)
259.jpeg)
258.jpeg)
